China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in Zhejiang. This recombinant protein vaccine is recommended by the national second dosage (fourth shot) booster immunization plan and is suitable for use in the elderly, immune-compromised individuals, and populations with complications.
Vaccine Development and Technology
SCB-2019 was developed using Clover’s proprietary Trimer-Tag (protein trimerization) technology, a drug development platform that enables the production of novel, covalently-trimerized fusion proteins. This technology is designed to enhance the stability and immunogenicity of the vaccine. SCB-2019 was included in China’s emergency use program in December of last year.
Global Phase II/III SPECTRA Study Results
The latest results from the global Phase II/III SPECTRA study showed that vaccination with SCB-2019 provided 100% protection against severe cases and hospitalization caused by any COVID-19 strain. This high level of protection underscores the vaccine’s potential to significantly reduce the impact of the pandemic.
Market Availability and International Plans
The vaccine is expected to be made available in multiple provinces and cities in China during the first quarter of this year. Clover plans to make marketing filings for emergency use directly in selected countries, primarily in the Asia Pacific region and Latin America. This strategic move is expected to drive revenue through bilateral deals starting in 2023, expanding the vaccine’s reach and impact globally.-Fineline Info & Tech
